Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Latest Information Update: 23 May 2024
At a glance
- Drugs IGF-methotrexate (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors IGF Oncology
- 09 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 21 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.
- 21 Oct 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.